# Study of Ataluren (PTC124) in Hemophilia A and B

> **NCT00947193** · PHASE2 · TERMINATED · sponsor: **PTC Therapeutics** · enrollment: 13 (actual)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DRUG:** Ataluren

## Key facts

- **NCT ID:** NCT00947193
- **Lead sponsor:** PTC Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10-14
- **Primary completion:** 2011-08-30
- **Final completion:** 2011-08-30
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Study was terminated early due to Sponsor decision and not reflective of adverse safety findings.
- **Last updated:** 2020-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00947193

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00947193, "Study of Ataluren (PTC124) in Hemophilia A and B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00947193. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*